Back to all journals
journal articles
VIEWPOINT: WHEN IT COMES TO LECANEMAB (AND DONANEMAB), HOW MIGHT WE THINK ABOUT ‘REASONABLE AND NECESSARY’?
L.S. Schneider
J Prev Alz Dis 2023;3(10):342-343
CITATION:
L.S. Schneider ; (2023): Viewpoint: When It Comes to Lecanemab (and Donanemab), How Might We Think about ‘Reasonable and Necessary’?. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2023.73